Age, years |
63.9 ± 7.9 |
PSA, ng/dL |
6.49 (4.7-9.5) |
Prostate volume, ml |
45 (33-62.5) |
PSAD, ng/dl/ml |
0.14 (0.10-0.23) |
Biopsy results, n(%)
Benign
PCa
|
121 (41.7)
169 (58.3)
|
PI-RADS score, n (%) |
|
II |
17 (5.9) |
III |
77 (26.6) |
IV |
165 (56.9) |
V |
31 (10.7) |
MRI lesion size, mm |
9.5 (7-13) |
Clinical T-stage |
|
T1c |
240 (82.8) |
T2 |
40 (13.8) |
T3 |
10 (3.4) |
ISUP grade, n(%) |
|
I |
65 (22.4) |
II |
51 (17.6) |
III |
34 (11.7) |
IV |
13 (4.5) |
V |
6 (2.1) |
RP, n(%) |
53 (18.3) |
Pathological T-stage, n(%)
T2a
T2b
T2c
T3a
T3b
|
9 (17.0)
5 (7.5)
19 (35.8)
17 (32.1)
4 (7.5)
|
EPE, n (%) |
22 (41.5) |
SM, n (%) |
16 (30.1) |
SVI, n (%) |
4 (7.5) |
Lymph node metastasis, n (%) |
1 (1.9) |